Literature DB >> 26770328

Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis.

Wei Liu1, Yuan-Hao Wu2, Lei Zhang1, Xiao-Ya Liu1, Bin Xue1, Yi Wang1, Bin Liu1, Qiao Jiang1, Hou-Wen Kwang1, Dong-Jing Wu1.   

Abstract

PURPOSE: A meta-analysis was undertaken to examine the correlation between ankylosing spondylitis (AS) progression and serum levels of pro-inflammatory cytokines, Interleukin-6 (IL-6) and Interleukin-17 (IL-17) in AS patients.
METHODS: PubMed, EBSCO, Cochrane Library database, Ovid, Springer link, WANFANG, China national knowledge infrastructure (CNKI) and VIP databases(last updated search in October, 2014) were exhaustively searched for published case-control studies using keywords related to IL-6, IL-17 and AS. The search results were screened using stringent inclusion and exclusion criteria, and the data from selected high-quality studies was analyzed with Comprehensive Meta-analysis 2.0 software.
RESULTS: Thirteen case-control studies were selected for this meta-analysis and contained a pooled total of 514 AS patients and 358 healthy controls. Our main result revealed strikingly higher serum levels of IL-6 and IL-17 in AS patients, compared to healthy controls (IL-6: SMD = 2.51, 95% CI = 1.33~3.70, P = 0.01; IL-17: SMD = 3.05, 95% CI = 2.09~4.02, P < 0.001). Ethnicity-based subgroup analysis showed a statistically correlation of high IL-6 and IL-17 serum levels with AS both in Asian (IL-6: SMD = 3.15, 95% CI = 0.75~5.55, P < 0.001; IL-17: SMD = 3.30, 95% CI = 1.93~4.66, P < 0.001) and Caucasian populations (IL-6: SMD = 1.34, 95% CI = 0.33~2.35, P = 0.009; IL-17: SMD = 2.52, 95% CI = 1.06~3.98, P = 0.001).
CONCLUSION: Meta-analysis of pooled data from thirteen high-quality studies revealed a strong correlation between elevated IL-6 and IL-17 serum levels and the development of AS. Therefore, IL-6 and IL-17 could be used as markers for diagnosis and assessment of treatment outcomes in AS patients.

Entities:  

Keywords:  Ankylosing spondylitis; interleukin-17; interleukin-6; meta-analysis; rheumatism; spondyloarthropathies

Year:  2015        PMID: 26770328      PMCID: PMC4694228     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  42 in total

Review 1.  Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications.

Authors:  Abdellah El Maghraoui
Journal:  Eur J Intern Med       Date:  2011-07-13       Impact factor: 4.487

Review 2.  Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis.

Authors:  Ernest Choy
Journal:  Rheumatology (Oxford)       Date:  2012-07       Impact factor: 7.580

3.  Heterogeneity testing in meta-analysis of genome searches.

Authors:  Elias Zintzaras; John P A Ioannidis
Journal:  Genet Epidemiol       Date:  2005-02       Impact factor: 2.135

4.  Testing overall and moderator effects in random effects meta-regression.

Authors:  Hilde M Huizenga; Ingmar Visser; Conor V Dolan
Journal:  Br J Math Stat Psychol       Date:  2011-02       Impact factor: 3.380

5.  IL-17 patterns in synovium, serum and synovial fluid from treatment-naïve, early rheumatoid arthritis patients.

Authors:  Anca Roşu; Cl Mărgăritescu; A Stepan; Anca Muşetescu; M Ene
Journal:  Rom J Morphol Embryol       Date:  2012       Impact factor: 1.033

6.  Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis.

Authors:  Wei-Sheng Chen; Yu-Sheng Chang; Kuan-Chia Lin; Chien-Chih Lai; Shu-Hung Wang; Kai-Hung Hsiao; Hui-Ting Lee; Ming-Han Chen; Chang-Youh Tsai; Chung-Tei Chou
Journal:  J Chin Med Assoc       Date:  2012-07-06       Impact factor: 2.743

7.  Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFalpha antagonist therapy.

Authors:  Daniel Wendling; Jean-Pierre Cedoz; Evelyne Racadot
Journal:  Joint Bone Spine       Date:  2008-10       Impact factor: 4.929

8.  The association between serum levels of potential biomarkers with the presence of factors related to the clinical activity and poor prognosis in spondyloarthritis.

Authors:  John Londono; Maria Consuelo Romero-Sanchez; Viviana Garcia Torres; Wilson A Bautista; Diego Jaimes Fernandez; Julitte de Avila Quiroga; Rafael Valle-Oñate; Ana María Santos; Juan Francisco Medina
Journal:  Rev Bras Reumatol       Date:  2012-08

9.  Effects of Tripterygium glycosides on interleukin-17 and CD4+CD25+CD127low regulatory T-cell expression in the peripheral blood of patients with ankylosing spondylitis.

Authors:  Wei Ji; Honggang Li; Feng Gao; Yajun Chen; Lingyu Zhong; Dan Wang
Journal:  Biomed Rep       Date:  2014-03-24

10.  Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy.

Authors:  Jenny L McGovern; Dao X Nguyen; Clare A Notley; Claudia Mauri; David A Isenberg; Michael R Ehrenstein
Journal:  Arthritis Rheum       Date:  2012-10
View more
  13 in total

Review 1.  Targeting the interleukin-23/17 axis in axial spondyloarthritis.

Authors:  Ananta Paine; Christopher T Ritchlin
Journal:  Curr Opin Rheumatol       Date:  2016-07       Impact factor: 5.006

2.  Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.

Authors:  Désirée van der Heijde; Atul Deodhar; James C Wei; Edit Drescher; Dona Fleishaker; Thijs Hendrikx; David Li; Sujatha Menon; Keith S Kanik
Journal:  Ann Rheum Dis       Date:  2017-01-27       Impact factor: 19.103

3.  Gene Expression Analysis before and after Treatment with Adalimumab in Patients with Ankylosing Spondylitis Identifies Molecular Pathways Associated with Response to Therapy.

Authors:  Marzia Dolcino; Elisa Tinazzi; Andrea Pelosi; Giuseppe Patuzzo; Francesca Moretta; Claudio Lunardi; Antonio Puccetti
Journal:  Genes (Basel)       Date:  2017-04-24       Impact factor: 4.096

4.  Influence of ad Libitum Feeding of Piglets With Bacillus Subtilis Fermented Liquid Feed on Gut Flora, Luminal Contents and Health.

Authors:  Yuyong He; Chunxia Mao; Hong Wen; Zhiyu Chen; Tao Lai; Lingyu Li; Wei Lu; Huadong Wu
Journal:  Sci Rep       Date:  2017-03-14       Impact factor: 4.379

Review 5.  Advances in nanomedicine for the treatment of ankylosing spondylitis.

Authors:  Yanhai Xi; Tingwang Jiang; Birendra Chaurasiya; Yanyan Zhou; Jiangmin Yu; Jiankun Wen; Yan Shen; Xiaojian Ye; Thomas J Webster
Journal:  Int J Nanomedicine       Date:  2019-10-29

6.  Positive association of Parkinson's disease with ankylosing spondylitis: a nationwide population-based study.

Authors:  Fu-Chiang Yeh; Hsiang-Cheng Chen; Yu-Ching Chou; Cheng-Li Lin; Chia-Hung Kao; Hsin-Yi Lo; Feng-Cheng Liu; Tse-Yen Yang
Journal:  J Transl Med       Date:  2020-11-30       Impact factor: 5.531

7.  Genetic Associations Between IL-6 and the Development of Autoimmune Arthritis Are Gender-Specific.

Authors:  Jianqiao Hong; Zihao Qu; Xiaoxiao Ji; Congsun Li; Geng Zhang; Ciliang Jin; Jie Wang; Yongxing Zhang; Yue Shen; Jiahong Meng; Chenhe Zhou; Chaohua Fang; Wei Wang; Shigui Yan
Journal:  Front Immunol       Date:  2021-09-03       Impact factor: 7.561

Review 8.  Recent advances in ankylosing spondylitis: understanding the disease and management.

Authors:  Leticia Garcia-Montoya; Hanna Gul; Paul Emery
Journal:  F1000Res       Date:  2018-09-21

9.  Short-Term Efficacy and Safety of Secukinumab for Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of RCTs.

Authors:  Yu Zhou; Jinhui Ma; Juncheng Ge; Bailiang Wang; Debo Yue; Weiguo Wang
Journal:  Mediators Inflamm       Date:  2020-10-26       Impact factor: 4.711

Review 10.  Interleukin-17A Interweaves the Skeletal and Immune Systems.

Authors:  Mengjia Tang; Lingyun Lu; Xijie Yu
Journal:  Front Immunol       Date:  2021-02-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.